Compare Nuvation Bio Inc. Class A Common Stock (NUVB) vs TD SYNNEX Corporation Common Stock (SNX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvation Bio Inc. Class A Common Stock vs TD SYNNEX Corporation Common Stock — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $4.71 (market cap $1.66B), while TD SYNNEX Corporation Common Stock trades at $256.5 (market cap $21.04B). The key difference: TD SYNNEX Corporation Common Stock is far larger — about 12.7× Nuvation Bio Inc. Class A Common Stock's market cap, and TD SYNNEX Corporation Common Stock pays a 0.73% dividend while Nuvation Bio Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 6 Days and TD SYNNEX Corporation Common Stock for 0 Days on average.
| NUVB | SNX | |
|---|---|---|
Market Cap | $1.66B | $21.04B |
Volume | 7,608,075 | 641,037 |
Sector | Health | Technology |
52-Week High | $9.54 | $290.14 |
52-Week Low | $3.41 | $142.42 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $1.25B | $25.81B |
Dividend Yield | — | 0.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nuvation Bio (NUVB) trades at $4.72, down 3.67% today, with a bearish technical outlook despite strong analyst support. The biopharma company shows promising revenue growth with $170M projected for 2026 but remains unprofitable with negative margins. Recent FDA approval for IBTROZI and Fast Track designation for safusidenib provide clinical catalysts, though cash burn remains elevated with -$121M operating cash flow in 2026.
Wall Street maintains strong bullish sentiment with 80% buy ratings and $20.50 price target (334% upside), but investors face significant execution risk as the company burns cash to commercialize new oncology therapies. The stock offers high-risk, high-reward potential dependent on successful commercialization and path to profitability.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →About TD SYNNEX Corporation Common Stock
TD SYNNEX Corporation is a global IT distributor and solutions aggregator that distributes endpoint devices and data-center technologies from technology vendors to resellers and customers worldwide.
Read more on SNX →
